BIA
MENS

Bell Investment Advisors’s Jyong Biotech MENS Stock Holding History

Bell Investment Advisors’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$427 Sell
206
-267
-56% -$566 ﹤0.01% 1760
2026
Q1 		$1.02K Buy
+473
New +$1.16K ﹤0.01% 1543

Other funds holding MENS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bell Investment Advisors's MENS Position: Q2 2026 in Review

Bell Investment Advisors reduced its Jyong Biotech (MENS) stake by 56% in Q2 2026, selling an estimated $566 and leaving 206 shares worth $427. The position accounts for ﹤0.01% of the portfolio, ranked #1760.

Bell Investment Advisors first reported a position in MENS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.02K in Q1 2026. 19 funds tracked by Wall St. Rank hold MENS as of Q2 2026.

  • Bell Investment Advisors held 206 shares of Jyong Biotech worth $427 as of Q2 2026.
  • Bell Investment Advisors sold 267 Jyong Biotech shares in Q2 2026, an estimated $566.
  • Jyong Biotech made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1760 holding.
  • Bell Investment Advisors first reported a position in Jyong Biotech in Q1 2026 and has held it in 2 quarters since.
  • Bell Investment Advisors's Jyong Biotech position peaked at $1.02K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Jyong Biotech as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.